NATCO RECEIVES GENERIC SOFOSBUVIR (SOVALDI®) APPROVAL FOR INDIA

Hyderabad, India, March 12th, 2015

Natco Pharma Limited (NSE: NATCOPHARM; BSE: 524816) is pleased to announce that it is the 1st company in India to get approval for generic sofosbuvir tablets, 400mg, from Drugs Controller General (India).  Sofosbuvir is a medicine used for chronic hepatitis C infection and sold globally by Gilead Sciences, Inc.,under its brand Sovaldi®.

Natco will market generic sofosbuvir under its brand HEPCINAT and through strategic partners in India. Natco plans to price its generic medicine at an MRP of INR 19,900 for a bottle of 28 tablets and expects to launch in India very soon. Natco had recently signed a non-exclusive licensing agreement with Gilead Sciences, to manufacture and sell generic versions of its chronic hepatitis C medicines in 91 developing countries.